Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $1.2 million.

  • Ocular Therapeutix's Depreciation & Amortization (CF) rose 3112.51% to $1.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.3 million, marking a year-over-year increase of 1418.38%. This contributed to the annual value of $4.3 million for FY2025, which is 1418.38% up from last year.
  • According to the latest figures from Q4 2025, Ocular Therapeutix's Depreciation & Amortization (CF) is $1.2 million, which was up 3112.51% from $1.1 million recorded in Q3 2025.
  • Ocular Therapeutix's Depreciation & Amortization (CF)'s 5-year high stood at $1.2 million during Q4 2025, with a 5-year trough of $483000.0 in Q1 2023.
  • Its 5-year average for Depreciation & Amortization (CF) is $781100.0, with a median of $771000.0 in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first tumbled by 1454.27% in 2021, then surged by 9511.2% in 2023.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Depreciation & Amortization (CF) stood at $570000.0 in 2021, then decreased by 13.86% to $491000.0 in 2022, then skyrocketed by 95.11% to $958000.0 in 2023, then decreased by 0.73% to $951000.0 in 2024, then surged by 31.13% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q4 2025, $1.1 million for Q3 2025, and $1.0 million during Q2 2025.